Objective To investigate the effect of the decoction to help recover intestinal function on the intestinal mucosal barrier of rats with gut ischemia-reperfusion injury. Methods Forty-five SD rats were divided into three groups randomly: control group,gut ischemia-reperfusion injury group and decoction group.We detected the content of DAO and D-lactate in serum and lysozyme in perfusate of intestine in each group.We observed the bacteria translocation,the change of ileum mucous membrane in pathomorphology and intestinal villi. Results Compared with those in gut ischemia-reperfusion injury group,the contents of DAO and D-lactate and bacteria translocation ratio were all lower in decoction group(P

Currently, the resistance of first-line anti-tuberculosis drugs has made the prevention and treatment of tuberculosis increasingly difficult, posing a serious threat to global public health. Several studies have shown that efflux pumps are one of the important causes for bacteria to develop multi-drug resistance and extremely-drug resistance, and efflux pump inhibitors can inhibit the efflux of antibacterial drugs, thereby reducing bacterial drug resistance. Numerous natural products and synthetic compounds have been reported to possess efflux pump inhibitory activity, but they have not been applied in clinical settings because of their toxicity, pharmacokinetic properties, etc. Therefore, we summarized the efflux pump inhibitory activity, antimicrobial activity, and structure-activity relationships of reported efflux pump inhibitors against Mycobacterium tuberculosis in recent years, providing references for the development of new efflux pump inhibitors with better activity and lower toxicity.

OBJECTIVETo investigate diagnostic efficacy of transvaginal three-dimensional hysterosalpingo-contrast sonography (3D-HyCoSy) in assessing tubal patency with chromolaporoscopy.

METHODSA total of 157 infertile women underwent 3D-HyCoSy to evaluate tubal patency. Among these patients, 39 patients were also examined by chromolaporoscopy. The concordance of the two clinical assessment methods was analyzed by the Kappa coefficient test.

RESULTSAmong the 306 oviducts examined by 3D-HyCoSy, 99 (32.4%) were patent, 126 (41.2%) partially obstructed, and 81 (26.5%) completely obstructed. Diagnostic results with 3D-HyCoSy were not statistically different from those obtained in the 39 women (78 oviducts) who also underwent chromolaporoscopy, and the two methods showed a high concordance (k=0.747, P=0.000). The 3D-HyCoSy procedure had a sensitivity of 84.8% (28/33), a specificity of 96.2% (25/26), and positive and negative predictive values of 93.3% (28/30) and 86.2% (25/29) respectively.

CONCLUSIONTransvaginal 3D-HyCoSy can accurately reveal the spatial path and morphology of the oviduct and is a safe and effective method to evaluate tubal patency.

Contrast Media ; Fallopian Tube Patency Tests ; methods ; Fallopian Tubes ; diagnostic imaging ; Female ; Humans ; Hysterosalpingography ; Imaging, Three-Dimensional ; Infertility, Female ; diagnostic imaging ; Laparoscopy ; Ultrasonography

Adolescent ; Child ; Female ; Ghrelin ; blood ; Glucose ; pharmacology ; Humans ; Male ; Obesity ; blood ; Time Factors

Objective:To analyze the clinical features and genetic factors of neonatal 17β-hydroxysteroid dehydrogenase type10 (HSD10) deficiency.Methods:The clinical characteristics and genetic test results of a child with HSD10 deficiency coming from Children′s Hospital of Nanjing Medical University in April 2019 were retrospectively analyzed.The keywords" 17β-hydroxysteroid dehydrogenase type 10 deficiency" or " 2-Methyl3-Hydroxybutyryl-CoA dehydrogenase deficiency" or " HSD10" , etc.were searched in various databases, including CNKI, Wanfang, Weipu, Embase and PubMed to review the cases collected from all published data until May 31, 2020.Results:The patient was a newborn male who developed symptoms on the first day after birth.The main signs were metabolic acidosis, increased blood ammonia and lactate, and hypotonia.Trio whole exom sequencing in the patient and his parents identified hemizygous NM001037811: c.650G>A, p.R217Q in the HSD17B10 gene that is inherited from the mother.Since the child died on the third day after birth, no further central nervous system examination was performed.The mother of the child has intellectual disability, the sibling sister is normal and the HSD17B10 locus is wild type.By lite-rature reviewing, 5 newborn cases with clear medical records and genetic test results were listed.All patients were male, and had onset of HSD10 deficiency within 1 week after birth.The main phenotypes include metabolic acidosis (increased blood ammonia and lactate), hypoglycemia, hypotonia, and convulsions.All 6 children died in early infancy.The corresponsive HSD17B10 variants were c. 740A>G/p.N247S, c.677G>A/p.R226Q, c.257A>G/p.D86G and c. 650G>A/p.R217Q, which did not indicate the hot spots of mutation. Conclusions:HSD10 deficiency in the neonatal period is relatively rare.The clinical diagnosis is difficult due to the serious condition and short course of the disease.Severe metabolic acidosis, hypotonia, and convulsions in neonatal patients are the main reasons for the poor prognosis, which can be attributed to the hemizygous variation and heterogeneity of the mutation site in male patients.c.650G>A may be closely associated with severe neonatal HSD10 deficiency, but the molecular biological mechanism needs to be further clarified.HSD10 deficiency has a poor prognosis and lacks effective treatment.

For screening the potential drugs as anti-liver fibrosis candidates, we established a high- throughput drug screening cell model based on COL1A1 promoter. The activity of COL1A1 promoter and luciferase reporter gene can be elevated by TGF-β1, and inhibited by candidate drugs. We constructed a recombined plasmid with COL1A1 promoter and luciferase reporter gene pGL4.17, the activity of COL1A1 promoter was reflected by fluorescence intensity. COL1A1 promoter activity was detected by Dual-Luciferase Reporter Assay System, it came that the relative luciferase activity of COL1A1 promoter was 15.98 times higher than that of control group induced by TGF-β1, showing the recombined plasmid could be used in cell model. The recombined plasmid was transfected into human hepatic stellate cells LX2, detected the effect of potential drugs, and obtained a stable expression system through stable transfection and monoclonal cell culture. A sample which could reduce COL1A1 promoter activity signally by our cell model, decreased collagen I mRNA and protein expression detected by real-time RT-PCR and Western blotting. It indicates this novel cell model can be used in high-throughput drug screening of potential anti-liver fibrosis drugs.
Collagen Type I ; genetics ; Drug Evaluation, Preclinical ; methods ; Genes, Reporter ; Hepatic Stellate Cells ; High-Throughput Screening Assays ; Humans ; Liver Cirrhosis ; drug therapy ; Luciferases ; Plasmids ; Promoter Regions, Genetic ; RNA, Messenger ; Transfection ; Transforming Growth Factor beta1 ; pharmacology

BACKGROUND:Compared with conventional medications, drug micro-capsule system can control the release of drugs and have wel target properties and biocompatibility. The drugs can be concentrated at the focus and play an important role in clinic. OBJECTIVE:To prepare dacarbazine magnetic micro-capsules with different capsule materials and gelatin complex by coacervation, and to optimize capsule materials and preparation process. METHODS:Fe 3 O 4 RESULTS AND CONCLUSION:The solution complex coacervation method was better than the emulsion coacervation method. As for the solution complex coacervation method, the optimal capsule material was gelatin-sodium alginate, with drug embedding rate 37.90%, the yield rate 72.31%, and the average magnetization intensity 8.53 emu/g. The second material was gelatin-chitosan. As a capsule material, the gelatin was better than chitosan with single coagulation method. Drug embedding rate was 51.58%, the yield rate was 64.50%, and the average magnetization was 6.93 emu/g. Single coagulation method was better than coacervation method. complex coacervation, we prepared the gelatin-Arabic gum magnetic micro-capsule, gelatin-sodium alginate magnetic micro-capsules, gelatin-sodium carboxymethyl cel ulose magnetic micro-capsules, and gelatin-chitosan magnetic micro-capsules. With the emulsion complex coacervation method, we further prepared the gelatin-Arabic gum magnetic micro-capsule, gelatin-sodium alginate magnetic micro-capsules, gelatin-sodium carboxymethyl cel ulose magnetic micro-capsules, and gelatin-chitosan magnetic micro-capsules. The magnetic gelatin micro-capsules and magnetic chitosan micro-capsules were prepared with single coagulation method. The micro-capsules were determined for the embedding rate, the magnetic susceptibility, the micro-capsule size and the release performance, to define the optimal preparation technology of dacarbazine magnetic micro-capsules.

Objective:To analyze the immunogenicity of the extracellular region of Δ42PD1.Methods: Six fragments ofΔ42PD1 extracellular region-encoding sequence were amplified by PCR, and were cloned into pCTCON2 vector, a yeast surface displaying vector.Yeast cells were transfected with Δ42PD1 fragment-carrying plasmids, then yeast cells were spread on SDCAA plates.Single cell clones were selected and cultured in SGCAA media to induce expression of the target genes.Mouse anti-humanΔ42PD1 anti-serum were generated by immunization of BALB/c mice via intramuscular injection ofΔ42PD1-carrying plasmid plus in-situ electroporation.The binding of anti-serum with yeast cells surface-displaying Δ42PD1 fragments were analyzed using flowcytometry.Results:Nucleotide sequences analysis indicated that the amplified six fragments ofΔ42PD1 sequence length were 110 bp,and the isolated sequence ofΔ42PD1 fragments were 100%homology with PD1 gene previously registered in GenBank.Results from flowcytometry showed that among the six fragments of Δ42PD1 displaying on the surface of yeast cells,F3 and F2 profoundly boundΔ42PD1-specific polyclonal antibodies.Conclusion:F3 and F2 ofΔ42PD1 is an immunogenic dominant region,which pave the way for generation of Δ42PD1-specific monoclonal antibody and epitope mapping.

Animals ; Antiviral Agents ; pharmacology ; therapeutic use ; DNA-Directed RNA Polymerases ; antagonists & inhibitors ; Drug Discovery ; Hemagglutinin Glycoproteins, Influenza Virus ; chemistry ; metabolism ; Humans ; Influenza A virus ; drug effects ; genetics ; metabolism ; Influenza, Human ; drug therapy ; Molecular Targeted Therapy ; Neuraminidase ; antagonists & inhibitors ; RNA-Binding Proteins ; antagonists & inhibitors ; Signal Transduction ; drug effects ; Viral Core Proteins ; antagonists & inhibitors ; Viral Matrix Proteins ; antagonists & inhibitors

Objective is designed to observe the effect of the low molecular protein "SL Hong-Xin Blood-Increasing Capsules" on human iron deficiency anemia. Altogether 110 school children, 7 - 12 years old, with iron deficiency anemia (Hb < 120 g/L) were enrolled in this trial and were randomly and evenly divided into two groups. In the treatment group (n = 55), the "SL Hong-Xin Blood-Increasing Capsules" were orally adminitered for 30 days, two capsules at one time and two times a day, whereas in the control group (n = 55) blank capsules were given to the children in the same way as in the treatment group. Before and at the end of the trial period, peripheral blood samples were taken from fringers of the children to determine Hb content, hematocrit percentage, and free protoporphyrin content in red blood cells. Results showed that after trial the Hb content was (15.9 +/- 9.6) g/L in the treatment group, while that of the control group was only (5.3 +/- 4.3) g/L (P < 0.001). The hematocrit percentage markedly increased (P < 0.001) and protoporphyrin level markedly decreased (P < 0.001). In conclusion the active ingredient of "SL Hong-Xin Blood-Increasing Capsules" is low molecular protein iron, which is markedly effective for elevating Hb content and hematocrit percentage, and effective for decresing protoporphyrin content of children with iron deficiency anemia. Hence, the capsules could be used to improve nutritional anemia in children based on the "Functional Evaluation Procedure and Test Methods For Health-Care Food".